Brief: Ultimovacs ASA - Announces Positive 5-Year Overall Survival Update

Zelluna ASA

10/12/2020 07:04

Dec 10 (Reuters) - Ultimovacs ASA  ULTIMO.OL :
    * ULTIMOVACS ASA - ANNOUNCES POSITIVE 5-YEAR OVERALL SURVIVAL UPDATE FROM
    * ULTIMOVACS ASA -  ULTIMOVACS ASA - ANNOUNCES POSITIVE 5-YEAR OVERALL SURVIVAL UPDATE FROM
PHASE
I COMBINATION TRIAL EVALUATING UNIVERSAL CANCER VACCINE UV1 IN METASTATIC MELANOMA
    * ULTIMOVACS ASA - TODAY ANNOUNCED POSITIVE FIVE-YEAR OVERALL SURVIVAL (OS) DATA FROM PHASE
I
TRIAL EVALUATING COMPANY'S UNIVERSAL CANCER VACCINE, UV1, IN COMBINATION WITH CHECKPOINT
INHIBITOR, IPILIMUMAB, IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA
    * ULTIMOVACS ASA - AFTER 5-YEARS OF FOLLOW-UP, 50% OF PATIENTS IN OPEN-LABEL TRIAL WERE
STILL
ALIVE, PROVIDING ENCOURAGING SIGNALS OF LONG-TERM SURVIVAL BENEFIT FOR UV1 IN THIS LATE-STAGE
PATIENT POPULATION AND AS COMPARED TO HISTORICAL DATA OF IPILIMUMAB MONOTHERAPY
    * ULTIMOVACS ASA - THESE RESULTS REPRESENT THIRD CLINICAL TRIAL WITH UV1 TO PROVIDE POSITIVE
DATA
FOR 5-YEARS OF PATIENT FOLLOW-UP, FURTHER STRENGTHENING UV1'S PROFILE AS A SAFE AND POTENTIALLY
EFFECTIVE ADDITION TO IMMUNO-ONCOLOGY TREATMENT REGIMENS.
    * ULTIMOVACS ASA - PRIMARY ENDPOINTS FOR STUDY INCLUDED SAFETY AND TOLERABILITY OF UV1 AS
WELL AS
INITIAL SIGNS OF CLINICAL RESPONSE
    * ULTIMOVACS ASA - AS PER DATA CUT-OFF AT END OF NOVEMBER 2020, EVERY PATIENT IN TRIAL
REACHED AT
LEAST 60 MONTHS OF FOLLOW-UP POST TREATMENT WITH UV1 AND IPILIMUMAB
    * ULTIMOVACS ASA - AT FIVE-YEAR MARK, OS RATE WAS 50%, MEDIAN OS HAD NOT YET BEEN REACHED
AND
MEDIAN PROGRESSION FREE SURVIVAL (MPFS) WAS 6.7 MONTHS
    * ULTIMOVACS ASA - OVER COURSE OF FOLLOW-UP PERIOD, NONE OF PATIENTS EXPERIENCED ANY
UNEXPECTED
SAFETY ISSUES RELATED TO UV1

Source text for Eikon:  ID:nObifr9PCa 
Further company coverage:  ULTIMO.OL 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))